目的 探讨肾素血管紧张素原(angiotensinogen,AGT) M235T基因多态性与脑白质疏松症(Leukoaraiosis,LA)的相关性.方法 采用聚合酶链反应(PCR)及聚合酶链反应-限制片段长度多态性(PCR-RFLP)及Sequenom系统检测,经头部MRI确诊的202例脑白质疏松症患者及105例经MRI排除LA的正常对照者AGTM235T基因多态性.结果 脑白质疏松症患者AGTMT基因型及T等位基因频率与对照组有明显差异,两组间TF基因型差异无统计学意义.结论 AGT基因MT基因型和T等位基因可能与脑白质疏松症的发病相关.

Objective To observe the effect of pramipexole on the treatment of primary restless legs syndrome( RLS) . Methods To-tally 60 patients with primary RLS were randomly divided into the treatment group(n=30)and the control group(n=30). The treat-ment group was given pramipexole for 12 weeks while the control group was given madopar plus lorazepam. The international RLS study group rating scale(IRLS),Pittsburgh Sleep Quality Index(PSQI) and Hamilton Anxiety Scale(HAMD) were used to evaluate the effect. Results The treatment group showed significant improvement compared with control group. IRLS,PSQI and HAMA for patients declined in various degrees,and the differences were significant(P<0. 05). Conclusion Pramipexole can not only effectively im-prove RLS but also improve the sleep quality and ease anxiety with low adverse reaction in RLS patients.

Objective To investigate the clinical effect of nicergoline in treatment of elderly patients with chronic cerebrospinal venous insufficiency. Method Used random number table method to selected 162 cases of elderly patients with chronic cerebrovascular venous insufficiency from July 2012 to July 2014 in our hospital as research objects, they were divided into nicergoline group and routine group, 81 cases in each group. Routine group patients were treated with conventional methods, on the basis of conventional treatment, nicergoline group patients were treated with nicergoline. Clinical effects of the two groups were compared. Result Before treatment, the index [color Doppler ultrasound detection of vertebral artery and middle cerebral artery, the end diastolic velocity (Vd), peak systolic velocity (Vs), resistance index (RI), pulsatility index (PI)] were not signiifcant different (P>0.05);12 weeks after treatment, Vd, Vs, RI, PI of the two groups patients were signiifcantly improved than before treatment, the difference was signiifcant (P<0.05), and Vd, Vs, RI, PI of nicergoline group patients were superior to control group, the difference was signiifcant (P<0.05). MMSE scores of the two groups patients before treatment were not signiifcant different (P > 0.05);after treatment, MMSE scores of the two groups patients were signiifcantly increased than before treatment (P < 0.05), and MMSE scores of nicergoline group was (24.5±1.3) points, signiifcantly higher than routine group [(22.9±1.5) points], the difference was signiifcant (P<0.05). 12 weeks after treatment, total effective rate of nicergoline group was 91.36%, signiifcantly higher than routine group (76.54%), the difference was signiifcant (P<0.05).&nbsp;Conclusion Nicergoline can improve patients with elderly chronic cerebrospinal venous insufifciency clinical symptoms and brain blood lfows, and can signiifcantly improve the clinical treatment effect.